Welcome to the e-CCO Library!

P709: Endoscopic healing and clinical remission after administration of adalimumab to patients with Crohn's disease of the small intestine
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Viazis, N.(1)*;Koustenis, K.(1);Veretanos, C.(1);Mountaki, A.(1);Almpani, F.(1);Tsatsa, A.(1);Trikola, A.(1);Beka, H.(1);Arvanitis, K.(1);Georgiadi, T.(1);Nousias, G.(1);Mylonas, I.(1);Kozompoli, D.(1);Paparizou, N.(1);Karaouzas, L.(1);Papastergiou, V.(1);Archavlis, E.(1);Mela , M.(1);Christidou, A.(1);Varytimiadis , K.(1);Hatzievangelinou, C.(1);Katopodi, K.(1);Vienna, E.(1);Mantzaris, G.(1);
Created: Friday, 14 July 2023, 11:12 AM
P709: inflammatory bowel disease and colorectal cancer: analysis of a single center retrospective chart review
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Fragaki M., Bachlitzanaki M., Karmiris K., Theodoropoulou A., Vardas E., Paspatis G.

Created: Wednesday, 20 February 2019, 10:36 AM
P709: Is there a difference in adalimumab drug levels according to pen vs. syringe use: An international, multi-centre retrospective analysis
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Little1*, I. Chu1, E. van der Zanden2, E. Flanagan3, S. Bell3, M. Sparrow1, E. Shelton4, S. Connor2, X. Roblin5, M. Ward1

Created: Thursday, 21 February 2019, 9:14 AM
P710 The influence of probiotics to the efficacy of 5-ASA for the patients of ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. YASUDA, K. Uchiyama, T. Takagi, M. Kubota, S. Sugino, Y. Azuma, H. Kitae, T. Torii, S. Takayama, K. Inoue, K. Katada, K. Kamada, T. Ishikawa, H. Konishi, Y. Naito, Y. Itoh

Created: Thursday, 30 January 2020, 10:12 AM
P710: Changes of gut microbiome after anti-TNF-α therapy and the prediction of clinical remission in patients with active ulcerative colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: ShinShin, S.(1)*;Oh, H.N.(2);Moon, J.M.(1);Joo, H.J.(1);Sul, W.J.(2);Choi, C.H.(1);
Created: Friday, 14 July 2023, 11:12 AM
P710: Efficacy of therapeutic intervention for ulcerative colitis patients with the Mayo Endoscopic Score of 1
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Fukuda1*, M. Naganuma1, S. Sugimoto1, K. Ono1, K. Nanki1, S. Mizuno1, K. Kimura2, M. Mutaguchi1, K. Takabayashi2, N. Inoue3, H. Ogata2, Y. Iwao3, T. Kanai1

Created: Thursday, 21 February 2019, 9:14 AM
P710: The use of first-line biologics in patients with Crohn’s disease in Norway from 2011 to 2016
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

K. Anisdahl*1,2, S. Lirhus3, A. Medhus1, L. Buer1,2, H. O. Melberg3, B. Moum1,2, M. Lie Høivik1

Created: Friday, 22 February 2019, 9:41 AM
P710: Vitamin D deficiency is not associated with depression in IBD patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Frigstad S.O.*1,2,3, Høivik M.3,4, Jahnsen J.3,5, Dahl S.R.6, Cvancarova M.4,7, Grimstad T.8, Berset I.P.9, Huppertz-Hauss G.10, Hovde Ø.3,11, Torp R.12, Bernklev T.3,10, Moum B.3,4, Jelsness-Jørgensen L.-P.13,14

Created: Wednesday, 20 February 2019, 10:36 AM
P711 Carriage of the HLA-DQA1*05 allele is associated with a high risk of loss of response to adalimumab in patients with Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Guardiola Capón1, K. SERRA1, L. Rodríguez-Alonso1, E. Santacana2, A. Padró3, N. Padullés2, A. Ruiz-Cerulla1, C. Arajol1, B. Camps1, G. Surís1, J. Orobitg1, F. Rodríguez-Moranta1

Created: Thursday, 30 January 2020, 10:12 AM
P711: A pilot study using point of care testing for infliximab and faecal calprotectin in IBD patients with a secondary loss of response
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Restellini1,2*, T. Bessissow1, C. Lemieux1, C.-Y. Chao1,3, G. Wild1, E. Seidman1, A. Bitton1, P.L. Lakatos1,4, W. Afif1

Created: Thursday, 21 February 2019, 9:14 AM
P711: Decreased steroid exposure and disease-related hospitalizations in patients with newly diagnosed inflammatory bowel disease in the era of newer biologic agents – A multi-centre experience in Singapore.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Yeo, G.D.D.(1)*;Qui, M.(2);Pak, W.C.W.(1);Tan, C.K.(3);Tay, S.W.(1);Lim, C.T.T.(1);Tan, T.K.M.(1);Ong, W.C.(4);Lim, T.G.(4);Ng, Y.T.V.(4);Wong, S.Y.A.(4);Salazar, E.(1);
Created: Friday, 14 July 2023, 11:12 AM
P711: Stool microbiome communities predict remission in pediatric Crohn’s disease patients even after start of treatment
Year: 2022
Source: ECCO'22
Authors: VerburgtMD, C.(1);Dunn, K.A.(2);Bielawski, J.P.(3);Otley, A.R.(4);Heyman, M.B.(5);Sunseri, W.(6);Shouval, D.(7);Levine, A.(8);de Meij, T.(1);Hyams, J.S.(9);Denson, L.A.(10);Kugathasan, S.(11);Benninga, M.A.(1);de Jonge, W.J.(12);Van Limbergen, J.E.(1);
Created: Friday, 11 February 2022, 3:56 PM
P711: The real-life experience of vedolizumab therapy in the OBSERV-IBD cohort: a 3-year prospective observational multi-centre cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Amiot*1, M. Serrero2, L. Peyrin-Biroulet3, J. Filippi4, B. Pariente5, X. Roblin6, A. Buisson7, C. Stefanescu8, C. Trang-Poisson9, R. Altwegg10, P. Marteau11, T. Vaysse12, A. Bourrier13, S. Nancey14, D. Laharie15, M. Allez16, G. Savoye17, J. Moreau18, L. Vuitton19, S. Viennot20, A. Aubourg21, A-L. Pelletier22, G. Bouguen23, V. Abitbol24, M. Fumery25, C. Gagniere1, Y. Bouhnik8

Created: Friday, 22 February 2019, 9:41 AM
P711: Vegetarian or gluten-free diet in patients with IBD – associated with lower psychological well-being and quality of life but no indication of beneficial effects on course of disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Schreiner P.*1, Rossel J.-B.2, Zeitz J.1, Misselwitz B.1, Scharl S.1, Scharl M.1, Frei P.3, Vavricka S.4, Pittet V.2, Rogler G.1, Biedermann L.1

Created: Wednesday, 20 February 2019, 10:36 AM
P712 Association of histologic-endoscopic mucosal healing after ustekinumab induction or maintenance therapy with 2-year outcomes in the UNIFI Phase 3 study in ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

K. Li1, F. Yang1, C. Marano1, H. Zhang2, W.J. Sandborn3, B.E. Sands4, B.G. Feagan5, D.T. Rubin6, L. Peyrin-Biroulet7, J.R. Friendman1, G. De Hertogh8

Created: Thursday, 30 January 2020, 10:12 AM
P712: Establishing pharmacokinetic equivalence between adalimumab and ABP 501 in the presence of anti-drug antibodies using population PK modelling
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Doshi*, E. Krishnan, H. Wang, N. Zhang, V. Chow

Created: Thursday, 21 February 2019, 9:14 AM
P712: Fungal microbiota composition in Inflammatory Bowel Disease patients in a Norwegian cohort: characterization of disease phenotypes and correlation with clinical activity and disease course.
Year: 2022
Source: ECCO'22
Authors: Catalàn-Serrax, I.(1,2,3);Thorsvik, S.(3,4);Beisvag, V.(2);Bruland, T.(2);Underhill, D.(3,5,6);Sandvik, A.K.(2,3,4);Van Beelen Granlund, A.(2,3,4);
Created: Friday, 11 February 2022, 3:56 PM
P712: Real-World Efficacy And Safety Of Ustekinumab And Adalimumab In Patients With Crohn's Disease: Propensity Matched Analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Shin, Y.(1);Hong, S.N.(1)*;Kim, E.R.(1);Chang, D.K.(1);Kim, Y.H.(1);
Created: Friday, 14 July 2023, 11:12 AM
P712: Risk factors for the development of fistulae and stenoses in Crohn's disease patients in the Swiss IBD cohort
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Zeitz J.*1, Fournier N.2, Labenz C.3, Biedermann L.4, Frei P.5, Misselwitz B.4, Scharl S.4, Vavricka S.4,6, Sulz M.7, Fried M.8, Rogler G.4, Scharl M.4

Created: Wednesday, 20 February 2019, 10:36 AM